INTRODUCTION
Atrial fibrillation (AF) is the most common heart rhythm disturbance, with a prevalence estimated between 2.7 and 6.1 million cases in the United States [1] . Compared to non-AF patients, AF patients have been found to be at a near five-fold higher risk of stroke and at an eight-fold higher risk of having multiple cardiovascular hospitalizations [2, 3] . The associated health care costs of patients with AF are high. The incremental cost burden of AF patients versus non-AF patients was estimated at $26 billion in the United States in 2010, with more than 50% of this amount being hospitalization costs [3, 4] . Moreover, the AFrelated hospitalization rate increased by 23% among US adults from 2000 to 2010 [5] .
Chronic anticoagulation has been the standard of care for patients with chronic nonvalvular atrial fibrillation (NVAF) in the previous decades and, until recently, warfarin and other vitamin K antagonists were the only available options [6, 7] . Recently, the targetspecific oral anticoagulants rivaroxaban, dabigatran, and apixaban have been approved by the US Food and Drug Administration (FDA) for the treatment of NVAF [8] [9] [10] . These new agents have predictable pharmacokinetic properties, minimal food-drug interactions, and do not require frequent monitoring as compared to warfarin [11] [12] [13] [14] . Recent studies have compared these new agents with warfarin and found that target-specific oral anticoagulants were a cost-effective option [15] [16] [17] .
AF is a significant driver of hospitalizations [18] and a considerable burden for the health care system. Since the use of new target-specific oral anticoagulants may result in potential economic benefits, the aim of the present study was to compare health care costs between NVAF patients using rivaroxaban and a matched sample of patients using warfarin.
METHODS

Data Source
The analysis was conducted using health insurance claims from the Humana database during the period from May 2011 through [23] [24] [25] . In each of the phase III trials, a total of 50-62% of patients had used warfarin before enrollment and randomization.
The observation period spanned from the date of the first dispensing (i.e., the first filled pharmacy prescription) of rivaroxaban or warfarin, defined as the index date, to the earliest among the end of data availability, end of insurance coverage, death, a switch to another anticoagulant, or 14 days after treatment nonpersistence (i.e., 14 days after the end of the days of supply of the first dispensing for which the next dispensing of the index medication, if any, was more than 60 days later). The nonpersistence criterion increased the certainty that health care costs were evaluated during exposure to the medications of interest.
Study Endpoints
The primary endpoint of this study was allcause health care costs, which included hospitalizations, ER visits, outpatient visits, and pharmacy costs. Health care costs were calculated as the sum of the following elements: amount paid by insurance, copay amount, coinsurance amount, deductible amount, and secondary insurance amount. AF-related costs were also evaluated. Costs for AF-related hospitalizations, ER visits, and outpatient visits were defined as costs associated with claims that had a primary or secondary diagnosis for AF. AF-related pharmacy costs were the costs of anticoagulant or antiplatelet agents that were dispensed.
Statistical Analysis
Propensity score matching was performed to adjust for confounding bias. Patients in the warfarin group were matched 1:1 to patients in the rivaroxaban group based on random selection among propensity score calipers of 5%. Propensity scores were calculated using a multivariate logistic regression model that incorporated the following baseline characteristics: age, gender, type of insurance, comorbidity index scores (i.e., Quan-Charlson Comorbidity Index, CHADS 2 score, CHA 2 DS 2 -VASc score, ATRIA score, and HAS-BLED score), baseline resource utilization, baseline costs, the month of the index date, and specific comorbidities ([5%; Table 1 ).
Patients' baseline characteristics evaluated during the 6 months prior to the index date were summarized using means [±standard deviation (SD)] for continuous variables, and frequencies and percentages for categorical variables. Baseline characteristics were compared between cohorts using standardized differences. Baseline characteristics with standardized differences of less than 10% were considered well balanced [26] [27] [28] .
Health care costs (i.e., hospitalizations, ER visits, outpatient visits, and pharmacy costs) between rivaroxaban and warfarin users were reported and compared using Lin's method to account for death and the censored observation periods of patients [29] . For the calculation of health care costs based on Lin's method, the follow-up period of each patient was partitioned in small intervals (i.e., days in the current study), and health care costs were calculated across all patients still observed (i.e., in plan and not censored) for a given interval. Hospitalizations, ER visits, outpatient visits, and pharmacy costs were estimated as the sum over intervals of the Kaplan-Meier estimator for the conditional probability of surviving to the start of the interval multiplied by the average studied outcome over the interval.
Health care costs were compared between cohorts through mean differences. Nonparametric bootstrap procedures with 999 replications were used to evaluate confidence intervals and to compare rivaroxaban and warfarin mean all-cause and AF-related costs.
All costs were inflation adjusted to 2012 US dollars based on the medical care component of the Consumer Price Index. Statistical significance was assessed at a significance level of 0.05. All statistical analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Characteristics
A total of 2253 rivaroxaban and 10,796 warfarin users were identified (Fig. 1 ). All rivaroxaban users were propensity matched with the same number of warfarin users to form the study cohorts. Overall, baseline characteristics were well balanced (i.e., standardized difference below 10%) between rivaroxaban and warfarin users. The baseline characteristics of the matched cohorts are summarized in Table 1 . Mean age of both cohorts was 74 years, and 46% of patients were female. All comorbidity index scores between cohorts were similar, with standardized differences below 10%, and the most prevalent comorbidities were hypertension, hyperlipidemia, diabetes, and abdominal surgery ([30%). A total of 517 (23%) rivaroxaban users had previous use of warfarin at baseline. The mean observation period was 114.0 and 123.7 days for rivaroxaban and warfarin users (standardized difference = 10.5%), respectively. 
DISCUSSION
This retrospective matched-cohort analysis compared health care costs between a sample of NVAF patients treated with the targetspecific oral anticoagulant rivaroxaban and a matched sample of NVAF patients treated with warfarin based on real-world data. 
; where p ¼ P warfarin þ P rivaroxaban ð Þ =2 c Evaluated during the 6-month baseline period Rivaroxaban was associated with a significant reduction in all-cause and AF-related estimated costs of hospitalization compared to warfarin (27% and 31%, respectively).
Significant differences between costs incurred by rivaroxaban and warfarin users were also found for estimated all-cause and AF-related outpatient visits (25% and 37%, respectively). Estimated pharmacy costs were significantly lower for warfarin users compared to rivaroxaban users (51% lower costs for allcause pharmacy costs and 95% for AF-related pharmacy costs).
Patients in the current study treated with rivaroxaban who had previous use of warfarin were classified in the rivaroxaban cohort. Since the results of the ROCKET AF trial suggested that rivaroxaban users who were naïve to warfarin experienced better primary efficacy and safety endpoints relative to warfarinexposed patients [24] , including warfarinexperienced patients in the rivaroxaban cohort likely produced more conservative estimates of differences between groups in the current study.
The proportion of rivaroxaban patients with prior use of warfarin in the current study at 23%
was lower than the proportion reported in the ROCKET AF trial, where 62% of rivaroxaban patients had previous use of vitamin K antagonists [24] . Since the current study was conducted with real-world data, it may be more representative of the real rivaroxaban patient population than a clinical trial with more strict inclusion criteria. for dabigatran users and $16,826 for warfarin users (P\0.01) [31] . Laliberté et al. [32] , who studied a Premier database sample of NVAF patients administered rivaroxaban or warfarin during a hospitalization, also found significantly lower hospitalization costs for rivaroxaban compared to warfarin users ($11,993 vs. $13,255, respectively; P\0.001).
Although patients with NVAF in the current study were not administered rivaroxaban or warfarin in a hospital setting, significantly lower hospitalization costs were also found for rivaroxaban compared to warfarin users ($5411 vs. $7427, respectively; P = 0.047) during the observation period. In addition, in the current study, total health care costs were not significantly different between rivaroxaban and warfarin users despite the significantly higher pharmacy costs of rivaroxaban users.
This suggests an offset of the higher cost of rivaroxaban therapy compared to warfarin. Recent cost-effectiveness studies have also been conducted to compare new target-specific agents with warfarin [15, 16, [33] [34] [35] . Harrington et al. [16] constructed a Markov decision analysis model using data from clinical trials and found that new agents (apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg) were all cost-effective alternatives to warfarin. 
